135 reports of this reaction
3.5% of all GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE reports
#3 most reported adverse reaction
DIZZINESS is the #3 most commonly reported adverse reaction for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, manufactured by RB Health (US) LLC. There are 135 FDA adverse event reports linking GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE to DIZZINESS. This represents approximately 3.5% of all 3,854 adverse event reports for this drug.
Patients taking GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 135 FDA reports for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 3.5% of all adverse event reports for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience dizziness while taking GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.